Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1208
Full metadata record
DC FieldValueLanguage
dc.contributor.authorXiang, Sue-
dc.contributor.authorStephens, Andrew-
dc.contributor.otherGao, Q.-
dc.contributor.otherWilson, K.-
dc.contributor.otherHeyerick, A.-
dc.contributor.otherPlebanski, Magdalena-
dc.date.accessioned2017-08-15T05:01:15Z-
dc.date.available2017-08-15T05:01:15Z-
dc.date.issued2017-06-
dc.identifier.citationEpworth Research Institute Research Week 2017; Poster 60: pp 84en_US
dc.identifier.urihttp://hdl.handle.net/11434/1208-
dc.description.abstractINTRODUCTION: Ovarian Cancer (OC) is the leading cause of death from gynaecological malignancy. Immunotherapeutic strategies are less toxic and more specific than current treatments. Sperm protein (sp17) is a cancer-testes antigen that is aberrantly expressed in ovarian and other cancers, but is generally undetectable on normal tissues. This restricted expression pattern makes SP17 an attractive target for the development of novel immunotherapies for OC. METHODS: Using SP17 overlapping peptides as vaccine targets, adjuvanted with CpG or nanoparticles, we assessed the induction of immune responses in vivo (in mice); as well as the anti-tumor activity of anti-Sp17 antibodies in vitro using OC cell lines. The study was approved by the Alfred Medical Research and Education Precinct (AMREP) animal ethics committee. RESULTS: 1) We identified a highly immunogenic region (hSp17111-142) in the human Sp17 sequence which induces high levels of antibodies and IFN-γ producing T cells both in C57BL/6 and in C57BL/6-HLA-A2.1 transgenic mice when adjuvanted with CpG or nanoparticles. Furthermore, immunization of C57BL/6 mice with CpG-adjuvanted hSp17111-142 significantly prolonged survival in our model of disseminated ovarian carcinoma. 2) We mapped the immuno-dominant B and T cell epitope regions within the hSp17111-142, and identified a single immuno-dominant B cell (134-142 aa) epitope and two T helper 1 (Th1) cell epitopes (111-124 and 124-138 aa). Our recent studies show that anti-hSp17111-142 serum antibody can directly kill the OC tumor cell lines derived from either mouse or human origins in vitro. Sp17 expression is indispensable for tumor survival in vivo, and highly co-localized with 2 markers associated with both tumor recurrence and acquired chemoresistance. CONCLUSION: Our finding provides an opportunity to design an immunotherapeutic regiment targeting Sp17 as a novel immunotherapeutic treatment for OC - particularly for patients with recurrent or chemoresistant disease. This discovery has been submitted for an international PCT patent.en_US
dc.subjectOvarian Canceren_US
dc.subjectOCen_US
dc.subjectNeoplasmsen_US
dc.subjectGynaecological Malignancyen_US
dc.subjectImmunotherapeutic Strategiesen_US
dc.subjectImmunotherapiesen_US
dc.subjectSperm Protein 17en_US
dc.subjectSP17en_US
dc.subjectCancer-Testes Antigenen_US
dc.subjectAntigensen_US
dc.subjectPeptidesen_US
dc.subjectVaccine Targetsen_US
dc.subjectAdjuvantsen_US
dc.subjectMiceen_US
dc.subjectIn Vivoen_US
dc.subjectIn Vitroen_US
dc.subjectImmunogenic Regionsen_US
dc.subjecthSp17111-142en_US
dc.subjectIFN-γen_US
dc.subjectT Cellsen_US
dc.subjectB Cellsen_US
dc.subjectEpitope Regionsen_US
dc.subjectC57BL/6en_US
dc.subjectC57BL/6-HLA-A2.1en_US
dc.subjectCpGen_US
dc.subjectDisseminated Ovarian Carcinomaen_US
dc.subjectTumor Recurrenceen_US
dc.subjectAcquired Chemoresistanceen_US
dc.subjectAlfred Medical Research and Education Precincten_US
dc.subjectAMREPen_US
dc.subjectCancer Services Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleTargeting sperm protein 17 for developing an immunotherapeutic treatment for ovarian cancer.en_US
dc.typeConference Posteren_US
dc.description.affiliatesDepartment of Immunology and Pathology, Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australiaen_US
dc.description.affiliatesOvarian Cancer Biomarker Laboratory, Hudson Institute of Medical Research, Victoria, Australiaen_US
dc.type.studyortrialIntervention Studyen_US
dc.description.conferencenameEpworth Research Institute Research Week 2017en_US
dc.description.conferencelocationEpworth Research Institute, Victoria, Australiaen_US
dc.type.contenttypeTexten_US
Appears in Collections:Cancer Services

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.